An Open-label, Single Sequence, 2-period Crossover DDI Study of Omaveloxolone in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-sequence, 2-period crossover study in healthy subjects.
In this study, 20 subjects will be enrolled to allow at least 16 evaluable subjects.
Subjects will receive a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) on Day
1 (Period 1) and on Day 29 (Period 2), and 600 mg efavirenz once a day from Days 15 through
42 (Period 2).